Roche Highlights Advances in Blood Disorder Treatments at ASH 2024
Key Insights
Roche will present over 40 abstracts at the 66th ASH meeting, showcasing advancements in lymphoma (search) and other blood disorders, reinforcing their commitment to hematology.
Five-year data from the POLARIX study shows a positive trend in overall survival for first-line diffuse large B-cell lymphoma (search) (DLBCL (search)) patients treated with Polivy in combination with R-CHP.
Extended follow-up data from studies of Lunsumio and Columvi demonstrate long-lasting remissions and immune system recovery in follicular lymphoma (search) and DLBCL (search), respectively.
Roche is set to present more than 40 abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7-10, 2024, in San Diego, USA. The presentations will cover nine blood disorders, emphasizing Roche's dedication to improving patient outcomes in lymphoma (search) through long-term follow-up data and novel investigational combinations.
Polivy Demonstrates Durable Remissions in DLBCL
Five-year data from the phase III POLARIX study (abstract #469) highlights the potential of Polivy (polatuzumab vedotin) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) to provide durable remissions in first-line diffuse large B-cell lymphoma (search) (DLBCL (search)). The study also shows a positive trend in overall survival (OS), marking significant progress in a disease area with limited advancements in nearly two decades.
Long-Term Data Supports Fixed-Duration Bispecific Antibodies
Extended follow-up data of up to four years from the pivotal GO29781 study of Lunsumio (mosunetuzumab) (abstract #4407) and the NP30179 study of Columvi (glofitamab) (abstract #865) demonstrate long-lasting remissions and immune system recovery after the end of treatment. These findings support the use of fixed-duration bispecific antibodies for third-line or later (3L+) follicular lymphoma (search) (FL) and DLBCL (search), respectively.
Subcutaneous Lunsumio Shows Promise
First presentation of data for a subcutaneous formulation of Lunsumio monotherapy from the pivotal phase II GO29781 study (abstract #1645) reveals high rates of deep and durable responses and low rates and severity of cytokine release syndrome in people with 3L+ FL. Subcutaneously administered Lunsumio could improve patient experience by combining shorter administration time with the existing benefits of a fixed-duration and outpatient therapy.
Quality of Life Maintained with Columvi Combination
New patient-reported outcomes data from the phase III STARGLO study (abstract #5132) indicate comparable health-related quality of life between treatment arms, despite a higher median number of cycles received with the Columvi combination (11 versus 4). These data, combined with the significant improvement in OS observed in the study, support the potential benefit for patients with second-line or later DLBCL (search).
Investigational Combinations Show Potential
New and updated data from investigational study combinations of Polivy with bispecific antibodies Lunsumio and Columvi in relapsed or refractory DLBCL (search), including the phase Ib/II NP39488 (abstract #988) and phase II GO40516 (abstract #989) studies, add to the growing body of evidence demonstrating the potential of novel bispecific antibody/Polivy combinations in earlier treatment lines, and support their ongoing phase III development.